GettyImages-1325076942.jpg

Our Pipeline

We have a rapidly expanding and advancing pipeline of novel monotherapy and combination product candidates that have shown a consistent safety profile and increasing evidence of efficacy surrogates such as biomarkers.

Stage

NG-347

Three transgenes:

producing membrane bound CD80 and secreted MIP1α and IFNα

T-cell attraction

and activation

NG-796A

Three transgenes:

producing IL-12, IL-15 and a chemokine

T-cell and

NK Cell 

activation

NG-XXX

Novel transgene combinations

Variety of mechanisms targeted

Product

Transgene

Payload

Principal

Mechanism

NG-350A

Two transgenes:

producing a secreted CD40 agonist monoclonal antibody

NG-641

Four transgenes:

producing an anti-FAP bispecific plus cytokines/ chemokines

CD40 Agonism

Phase 1

Phase 2

Phase 3

Research

IND

Enabling

Commercial Rights

Anti-

Stromal

Cartoon Virus 2.png
Psioxus 2 Transgene.png
Cartoon Virus 2.png
Psioxus 4 Transgene.png
Cartoon Virus 2.png
Cartoon Virus 2.png
Cartoon Virus 2.png
allwhite_dnastrand.png